Analyst Ratings For Mersana Therapeutics (NASDAQ:MRSN)

.

Some recent analyst ratings include

• 3/19/2018-JPMorgan Chase & Co. was Downgraded by analysts at JPMorgan Chase & Co. from a “Overweight ” rating to a ” Neutral” rating. They now have a $23.00 price target on the stock.
• 7/24/2017-Wedbush Reiterated Rating of Outperform .
• 7/24/2017-Leerink Swann initiated coverage with a Outperform rating.
• 7/24/2017-Cowen initiated coverage with a Outperform rating.

• On 7/3/2017 M James Barrett, Major Shareholder, bought 1,000,000 with an average share price of $15.00 per share and the total transaction amounting to $15,000,000.00.

Recent Trading Activity for Mersana Therapeutics (NASDAQ:MRSN)
Shares of Mersana Therapeutics closed the previous trading session at with 17.270000457763672 shares trading hands.